







VII CONGRESSO DI ECOCARDIOCHIRURGIA


*Milano 6 Maggio 2014  
Atahotel Executive*

**Il Ruolo della  
Valvuloplastica in Epoca TAVI  
nel Trattamento  
della Stenosi Valvolare Aortica dell' Anziano**

*Andrea Santarelli  
Dipartimento Malattie Cardiovascolari  
Ospedale Infermi, Rimini*



# Dilatazione Percutanea della Valvola Aortica




# Valvuloplastica Aortica: Effetti



Rottura dei noduli calcifici che creano dei punti cardini nelle cuspidi con il risultato di determinare una maggiore mobilità delle stesse

# Gradiente Medio TransValvolare: 69 mm Hg



# Gradiente Medio Post VAP: 33 mm Hg

Misurazione gradiente: Misure area valvolare

50 + [Icons]

Fase: Linea di base

Valvola: Aortica

GC: [ ] l/min

Gradiente: 33,16 mmHg

Periodo eiezione sistolica: 21,27 s/minuto

Area valvolare [ ] cm<sup>2</sup>

Flusso valvolare [ ] ml/s

Manuale

<<


<

>


>>

OK

Annulla




# Outcome Ospedaliero



# Valvuloplastica Aortica Percutanea: Outcome al FU

*674 pz trattati con VAP dal 1987 al 1989  
Registro NHLBI*





# Outcome Ospedaliero

Complication	n (%)		
Death	17 (3)	Respiratory	
<b>Patients with any severe complication</b>	<b>167 (25)</b>	Intubation	28 (4)
Type of complication		Arrhythmia	
Hemodynamic		Treatment required	64 (10)
Prolonged hypotension	51 (8)	Persistent bundle-branch block	34 (5)
CPR required	26 (4)	AV block requiring pacing	30 (4)
Pulmonary edema	19 (3)	VF or VT requiring countershock	18 (3)
Cardiac tamponade	10 (1)	Vascular	
IABP use	11 (2)	Significant hematoma	44 (7)
Acute valvular insufficiency		Vascular surgery performed	33 (5)
Aortic	6 (1)	Systemic embolic event	11 (2)
Mitral	1 (0.1)	<b>Transfusion required</b>	<b>136 (20)</b>
Cardiogenic shock	15 (2)	Ischemic	
Neurological		Prolonged angina	9 (1)
Vasovagal reaction	36 (5)	Acute myocardial infarction	10 (1)
Seizure	15 (2)	Other severe complications	
Transient loss of consciousness	4 (0.6)	Pulmonary artery perforation	1 (0.1)
Focal neurological event	13 (2)	Acute tubular necrosis	1 (0.1)

# Linee Guida ESC 2012: Indicazioni alla Valvuloplastica Aortica Percutanea

This intervention can be considered as a **bridge to surgery in haemodynamically unstable** patients who are at high risk for surgery (recomendations class IIb, level of evidence C)

or in patients with symptomatic severe AS who require **urgent major non cardiac surgery** (recomandations class IIb, level of evidence C)”

As a **palliative** measure in selected individual cases when surgery is controindicted because of severe comorbidities and TAVI is not an option




# **Percutaneous Balloon Aortic Valvuloplasty Revisited**

## **Time for a Renaissance?**

Hideiko Hara, MD; Wesley R. Pedersen, MD; Elena Ladich, MD; Michael Mooney, MD;  
Renu Virmani, MD; Masato Nakamura, MD; Ted Feldman, MD; Robert S. Schwartz, MD

## Standalone Balloon Aortic Valvuloplasty: Indications and Outcomes From the UK in the Transcatheter Valve Era



423 pts in 25 UK centers with TAVI program, 2003 - 2010



## Standalone Balloon Aortic Valvuloplasty: Indications and Outcomes From the UK in the Transcatheter Valve Era


	No.(%) or mean (SD)
Age (years)	80.9 ± 8.5
Male	222 (52.5%)
Previous coronary artery disease	260 (61.5%)
Previous CABG	52 (12.3%)
Previous PCI	49 (11.6%)
Previous BAV	9 (2.1%)
Previous noncoronary thoracotomy	6 (1.5%)
Logistic Euroscore	27.8 ± 16.8
<b>Indication</b>	
Palliation	172 (40.7%)
Bridge to TAVI	144 (34.0%)
Bridge to sAVR	54 (12.8%)
<b>Presentation</b>	
Elective	191 (45.2%)
Urgent	178 (42.1%)
Emergency	54 (12.8%)

## Recovery After Balloon Aortic Valvuloplasty in Patients With Aortic Stenosis and Impaired Left Ventricular Function: Predictors and Prognostic Implications




# Tecnica Semplificata

Rapid Pacing



# Emostasi con Sutura Percutanea e Tecnica Pre-Close





**Standalone Balloon Aortic Valvuloplasty: Indications and Outcomes From the UK in the Transcatheter Valve Era**

## **Major Complications (6.3%)**

- Death: 2.4%
- Cardiac Tamponade: 1.0%
- Coronary Embolism: 0.5%
- Stroke: 1.0%
- Surgical Vascular Access Repair: 1.0%
- Permanent Pacemaker Implant: 0.2%
- Transfusion  $\geq$  2 Units Packed Red Cells: 1.2%


# Rimini VAP

## Complicanze Procedurali:

456 VAP Consecutive in 354 pz (mediana età 85, range 43-100)

	N	%
Morte (3 Tamponamenti)	4	0.8
NSTEMI	2	0.4
Ictus	1	0.2
Insufficienza Aortica Severa	1	0.2
Compl Vasc (Trasf e/o Chir Vasc)	6	1.3
Tamponamenti	6	1.3

# Percorso e snodi decisionali per i pazienti selezionati per TAVI




**How many patients with severe symptomatic aortic stenosis excluded for cardiac surgery are eligible for transcatheter heart valve implantation?**

Francesco Saia<sup>a</sup>, Cinzia Marrozzini<sup>a</sup>, Gianni Dall'Ara<sup>a</sup>, Vincenzo Russo<sup>b</sup>, Sofia Martin-Suárez<sup>c</sup>, Carlo Savini<sup>c</sup>, Paolo Ortolani<sup>a</sup>, Tullio Palmerini<sup>a</sup>, Nevio Taglieri<sup>a</sup>, Barbara Bordoni<sup>a</sup>, Emanuele Pilato<sup>c</sup>, Roberto Di Bartolomeo<sup>c</sup>, Angelo Branzi<sup>a</sup> and Antonio Marzocchi<sup>a</sup>

*“PABV was performed either as palliative procedure or as a bridge to TAVI in all our patients. This choice allow us to improve the clinical condition of clinically unstable patients, to increase the number of patients finally eligible for TAVI through the demonstration of LV function recovery and/or reduction of mitral valve regurgitation, and to reconsider surgery insome patients who were primarily considered as noncandidates for surgery”.*

*“In addition, through the analysis of patient response to PABV, we tried to predict more precisely the clinical benefit in the case of a subsequent TAVI procedure”.*

# Percorso e snodi decisionali per i pazienti selezionati per TAVI



# Development and Validation of a Prognostic Index for 4-Year Mortality in Older Adults


---

Lee et al, JAMA 2006; 295: 801-808

Totale = 8

Risk Factor	Adjusted OR (95% CI)*	Points
Demographics		
Age, y		
60-64	1.9 (1.4-2.5)	1
65-69	2.8 (2.1-3.7)	2
70-74	3.7 (2.8-4.9)	3
75-79	5.4 (4.1-7.1)	4
80-84	8.3 (6.3-11.0)	5
≥85	16.2 (12.2-21.6)	7
Male sex	2.0 (1.8-2.3)	2
Comorbidities and behaviors		
Diabetes mellitus	1.8 (1.5-2.1)	1
Cancer	2.1 (1.7-2.4)	2
Lung disease	2.3 (1.8-2.9)	2
Heart failure	2.3 (1.8-3.1)	2
BMI < 25	1.7 (1.4-1.9)	1
Current smoker	2.1 (1.7-2.5)	2
Functional measures		
Bathing	2.0 (1.6-2.4)	2
Managing finances	1.9 (1.6-2.3)	2
Walking several blocks	2.1 (1.8-2.4)	2
Pushing/pulling heavy objects	1.5 (1.3-1.8)	1


# 40% Possibilità di Sopravvivere a 4 anni





## Emerging indications, in-hospital and long-term outcome of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era

Francesco Saia<sup>1\*</sup>, MD, PhD; Cinzia Marrozzini<sup>1</sup>, MD; Cristina Ciuca<sup>1</sup>, MD; Paolo Guastaroba<sup>2</sup>, MSc; Nevio Taglieri<sup>1</sup>, MD; Tullio Palmerini<sup>1</sup>, MD; Barbara Bordonì<sup>1</sup>, MD; Carolina Moretti<sup>1</sup>, MD; Gianni Dall'Ara<sup>1</sup>, MD; Angelo Branzi<sup>1</sup>, MD; Antonio Marzocchi<sup>1</sup>, MD




## Standalone Balloon Aortic Valvuloplasty: Indications and Outcomes From the UK in the Transcatheter Valve Era


	No.(%) or mean (SD)
Age (years)	80.9 ± 8.5
Male	222 (52.5%)
Previous coronary artery disease	260 (61.5%)
Previous CABG	52 (12.3%)
Previous PCI	49 (11.6%)
Previous BAV	9 (2.1%)
Previous noncoronary thoracotomy	6 (1.5%)
Logistic Euroscore	27.8 ± 16.8
<b>Indication</b>	
Palliation	172 (40.7%)
Bridge to TAVI	144 (34.0%)
Bridge to sAVR	54 (12.8%)
<b>Presentation</b>	
Elective	191 (45.2%)
Urgent	178 (42.1%)
Emergency	54 (12.8%)

## Emerging indications, in-hospital and long-term outcome of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era

Francesco Saia<sup>1\*</sup>, MD, PhD; Cinzia Marrozzini<sup>1</sup>, MD; Cristina Ciuca<sup>1</sup>, MD; Paolo Guastaroba<sup>2</sup>, MSc; Nevio Taglieri<sup>1</sup>, MD; Tullio Palmerini<sup>1</sup>, MD; Barbara Bordoni<sup>1</sup>, MD; Carolina Moretti<sup>1</sup>, MD; Gianni Dall'Ara<sup>1</sup>, MD; Angelo Branzi<sup>1</sup>, MD; Antonio Marzocchi<sup>1</sup>, MD




## Standalone Balloon Aortic Valvuloplasty: Indications and Outcomes From the UK in the Transcatheter Valve Era




# Ripetizione della Valvuloplastica


Mount Sinai Hospital NY



**Rimini: BAV pts over 85 years ReDo (33 pts) vs no ReDo (75 pts) at 2 ys**




## ReDo vs no ReDo 2 ys mortality



## PARTNER study 2 ys mortality

### All Cause Mortality (ITT) Crossover Patients Followed

THE PARTNER TRIAL  
 $\Delta$  at 2 yr = 24.3%  
NNT = 4.1 pts




**C.L.: sopravvissuta 5 anni dalla 1° Valvuloplastica (3 ReDo)**






# Valvuloplastiche e TAVI in Italia 2012




# TAVI e Valvuloplastiche in Italia 2012

....se modello Bologna (Rimini)




# TAVI e Valvuloplastiche in Italia 2012

.....la realtà



# Rimini: Corsi Valvuloplastica

In 5 Anni 68 Cardiologi Interventisti da 47 Centri



Maddaloni